The CCL3L1 and CCL4L1 genes are found in a region of Human chromosome 17q12. These genes encode cytokines and the number of gene copies varies between individuals, with 0-4 copies in European individuals and 3-10 copies in African individuals. Copy number variations of these genes have been associated with various autoimmune diseases, possibly playing a role in rheumatoid arthritis susceptibility [PMID:17604289]. There are conflicting reports concerning how this region influences HIV infection and progression [PMID:15637236 and PMID:19812560].
In the NCBI36 reference, this region was comprised of clones from different libraries, and thus different haplotypes. A user reported that it seemed likely that the selected tiling path, that also contained a gap, did not represent a valid structure at this biomedically important locus. We have tracked the work on this region in HG-75. Despite our best efforts, we could not resolve all problems in this region in time for the release of GRCh37.
Because of the complexity of this region, we chose to produce a new tiling path using a BAC library that has been constructed from a hydatidiform mole library (CHORI-17). Complete hydatidiform moles are the result of a single sperm fertilizing an enucleated egg. The sperm reduplicates to generate two sets of the paternal chromosomes and thus contains DNA from a single haplotype. Clones from this resource have proven very useful for resolving highly duplicated genomic regions. The joins between the newly sequenced mole clones are of excellent quality, so we have a higher degree of confidence in the assembly of the new components than in the old, mixed-haplotype assembly.
The resultant pathway closes the gap and contains a single copy of each CCL3L1 and CCL4L1, providing a valid allele at this locus. The new pathway also contains five full copies of TBC1D3, two of which flank the CCL genes, and could provide a reasonable explanation for the generation of the null state resulting from the recombination between the CCL flanking copies of TBC1D3. Because of the clinical importance of this region, we released this sequence as part of patch release 2 (GL383560.1).
In the NCBI36 reference, this region was comprised of clones from different libraries, and thus different haplotypes. A user reported that it seemed likely that the selected tiling path, that also contained a gap, did not represent a valid structure at this biomedically important locus. We have tracked the work on this region in HG-75. Despite our best efforts, we could not resolve all problems in this region in time for the release of GRCh37.
Because of the complexity of this region, we chose to produce a new tiling path using a BAC library that has been constructed from a hydatidiform mole library (CHORI-17). Complete hydatidiform moles are the result of a single sperm fertilizing an enucleated egg. The sperm reduplicates to generate two sets of the paternal chromosomes and thus contains DNA from a single haplotype. Clones from this resource have proven very useful for resolving highly duplicated genomic regions. The joins between the newly sequenced mole clones are of excellent quality, so we have a higher degree of confidence in the assembly of the new components than in the old, mixed-haplotype assembly.
The resultant pathway closes the gap and contains a single copy of each CCL3L1 and CCL4L1, providing a valid allele at this locus. The new pathway also contains five full copies of TBC1D3, two of which flank the CCL genes, and could provide a reasonable explanation for the generation of the null state resulting from the recombination between the CCL flanking copies of TBC1D3. Because of the clinical importance of this region, we released this sequence as part of patch release 2 (GL383560.1).
I was diagnosed as HEPATITIS B carrier in 2013 with fibrosis of the
ReplyDeleteliver already present. I started on antiviral medications which
reduced the viral load initially. After a couple of years the virus
became resistant. I started on HEPATITIS B Herbal treatment from
ULTIMATE LIFE CLINIC (www.ultimatelifeclinic.com) in March, 2020. Their
treatment totally reversed the virus. I did another blood test after
the 6 months long treatment and tested negative to the virus. Amazing
treatment! This treatment is a breakthrough for all HBV carriers.